Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2017)
30 slides from Cyclopharm's shareholder meeting presentation, May 9, 2017
Slide 1: Cyclopharm Limited 2017 Annual General Meeting
For personal use only Cyclopharm Limited A profitable and growing market leader in nuclear medical imaging and lung healthcare 2017 Annual General Meeting 9 May 2017 1
Slide 2: Chairman's Address
For personal use only 2017 AGM Chairman’s Address David Heaney 2
Slide 3: Our Strategy
Our Strategy For personal use only CYC has a clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We will do this by: 1. Attaining approva
Slide 4: Managing Director's Review
For personal use only 2017 AGM Managing Director’s Review James McBrayer • Company Overview – Our Business • Investment Highlights • CYC’s 10 Fast Facts • Our Strategy • 2016 Achievements • 2016 Financial Results and Performance • Product Overview and Growth Opportunities ― Technegas ― Ultralute • 2
Slide 5: Our Business
Our Business…. Business Model Based on Annuity Stream From Consumables For personal use only Manufacturer and distributor of • Invented in 1986 lung ventilation imaging devices • Track record of growing revenue, and equipment profits and cash flows • USFDA trials for sales in US progressing • Functi
Slide 6: Investment Highlights – Record Results
Investment Highlights – Record Results For personal use only CYC is a leading player in the global nuclear medicine imaging and lung health markets • Technegas: Diagnosis & monitoring of lung diseases • UltraluteTM: Extends useful life of medical isotopes $ • 2016 Sales: • 2016 EPS: A$14.4 million
Slide 7: CYC's Fast Facts
CYC’s 10 Fast Facts For personal use only 1. Technegas is a well-established proprietary world leader in functional lung ventilation imaging technology with an annuity style product and service revenue streams with the majority of sales generated from single patient consumables. 2. Technegas is alre
Slide 8: Our Strategy
Our Strategy For personal use only CYC has a clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We are doing this by: 1. Attaining appro
Slide 9: 2016 Achievements
2016 Achievements For personal use only • FY2016 Sales of $14.39 million • FY2016 EBIT $1.44 million • Payment of recurring dividends • Cash reserves at 31 December totalling $4.59 million after repayment of debt & relocation • USFDA clinical trial program on track (time & budget) • Decision to move
Slide 10: 2016 Financial Results and Performance
2016 Financial Results and Performance For personal use only Third consecutive year of record underlying results • Another record financial Year ended 31 December ($000’s) 2016 Change 2015 Change 2014 result in FY16 Sales Revenue • Underlying strong financial PAS 10,782 6.3% 10,145 8.1% 9,384 perfor
Slide 11: Cyclopharm Group Balance Sheet
Cyclopharm Group Balance Sheet For personal use only Solid Financial Foundation to Leverage Growth Strategy • Operating cash flows supported $1.5m Kingsgrove HQ capex, ($000’s) FY 2016 FY 2015 FY 2014 $0.43m one-off relocation Cash 4,591 6,445 3,268 costs, ongoing USFDA trials Other current assets 6
Slide 12: Technegas – A Global Success Story
Technegas – A Global Success Story For personal use only • Technegas sold in 55 countries − Europe is the largest regional market for Technegas − In 2014 Canada became largest country market for Technegas, surpassing France • Over 210,000 patient studies in 2016 • Over 3,500,000 patient studies sinc
Slide 13: Technegas – USFDA Approval Within Reach
Technegas – USFDA Approval Within Reach For personal use only USA Market Size: • Half the world’s nuclear medicine departments are in the USA • USA represents a potential base Pulmonary Embolism market of 480,000 patients per annum. (Current Rest of the World volumes = 200,000 patients per annum) St
Slide 14: Ultralute: The Next Phase of Growth
UltraluteTM The Next Phase of Growth For personal use only Product Overview Technical Features • Disruptive Technology – changes 60 years of • Enables a user to extend the usable life of how radiopharmaceuticals are manufactured a Mo99 Generator • Extends the effective use of Mo99 generator • Allows
Slide 15: Ultralute Generational Overview & Mo99 Supply Chain
UltraluteTM Generational Overview & Mo99 Supply Chain For personal use only Molybdenum Manufacturing and Supply Chain • There are over 5,000 Mo99 generators sold worldwide each week. • 50% are sold to Radiopharmacy with U235 Hospitals/Clinics & Radiopharmacies the remaining 50% sold Targets directly
Slide 16: 2017 Strategic Priorities and Outlook
2017 Strategic Priorities and Outlook For personal use only Strategic Goals & Guidance Activity Timeframe United States • Commence patient recruitment May 2017 FDA Approval • Complete 10th clinical site installation Q3 2017 • Complete Technegas particulate study 2H 2017 • Submit preliminary report t
Slide 17: Formal Business
For personal use only 2017 AGM Formal Business David Heaney 17
Slide 18: 2017 AGM – Formal Business
2017 AGM – Formal Business For personal use only Proxy’s Resolution Business For Against Abstain Discretion 1 Remuneration report 40,875,490* 9,583 - - 2 Re-election of David Heaney 40,885,073* - - - 3 Election of Tom McDonald 40,885,073* - - - 4 Renewal of share buy-back capacity 33,229,371* 7,655,
Slide 19: Appendix Section
For personal use only Cyclopharm Limited Appendix Section • Cyclopharm History • Growth Opportunities and Key Performance Indicators • Technegas • Ultralute • MMI • Disclaimer 19
Slide 20: Our History
Our History For personal use only 1984 1992 2000 2001 2007 2013 Technegas European markets Vita Life Sciences USFDA Technegas Plus UltraluteTM discovered and established acquires program initiated generator launched technology commercialised Tetley Medical for Technegas established 1985 1995 2000 20
Slide 21: Growth Opportunities and Key Performance Indicators
Growth Opportunities and Key Performance Indicators For personal use only Technegas USA • The USA represents the single largest market with half of the world’s nuclear medicine departments located there • Existing market for PE in the USA equates to ~480,000 patients per annum • First priority follo
Slide 22: Growth Opportunities and Key Performance Indicators
Growth Opportunities and Key Performance Indicators For personal use only Ultralute MMI Cyclopet Market • Europe targeted as the Revenue Volumes closely aligned with Molecular Following competition from Penetration primary market to launch the hospital. Continued double Imaging government owned ente
Slide 23: Technegas Technology
Technegas Technology For personal use only Product Definition Technegas is composed of Tc‐99m labelled carbon nanoparticles Technegas is a System dispersed in high purity argon gas. In order to deliver efficacious clinical The particles are consistently well under 500 nm and due to the outcomes, Tec
Slide 24: Technegas – The Canadian Case Study
Technegas – The Canadian Case Study For personal use only • Canada is our largest single The Generator and Consumable Relationship country market with 13 consecutive years of PAS 50,000 140 growth Technegas Growth ‐ Canada 45,000 • Canada represents a strong Active Generators 120 indicator of USA ac
Slide 25: Evolution of Functional Lung Ventilation Imaging
Evolution of Functional Lung Ventilation Imaging For personal use only • Improvements in 3D imaging techniques, hybrid imaging and the advent of analytical software have dramatically improved the sensitivity and specificity in functional lung imaging with Technegas • Traditionally used in the diagno
Slide 26: Technegas – Global Indication Expansion
Technegas – Global Indication Expansion For personal use only Targeting Chronic Obstructive Additional indication and applications Pulmonary Disease (COPD) market – Asthma, Lung Reduction and CTEPH* Evaluating the effectiveness of Technegas in Technegas can provide the clinician the ability to early
Slide 27: Technegas Indication expansion – Targeting COPD in China
Technegas Indication expansion – Targeting COPD in China For personal use only • The Global incidence of Chronic Obstructive Pulmonary Disease (COPD) is 30x greater than that of Pulmonary Embolism (PE) • By 2030 COPD is estimated to be world’s 3rd highest cause of death • Between 2003 and 2033, it i
Slide 28: Ultralute 2017 Launch
UltraluteTM 2017 Launch - Targeting Direct Generator Users of Mo99 For personal use only • UltraluteTM v1 is targeted at the clinical end-user market • The European Mo99 generator market is completely Direct • UltraluteTM registration in the EU has been determined to be a laboratory apparatus • The
Slide 29: Macquarie Medical Imaging
Macquarie Medical Imaging For personal use only • Joint venture with: • 50% Alfred Health Solutions CT MRI PET • 30% Macquarie University • 20% Cyclopharm • Comprehensive suite of imaging modalities • State of the art research platform • Growth and profitability linked to ramp-up Cardiac CT Ultra‐so
Slide 30: Disclaimer
For personal use only Disclaimer Corporate Head Office Certain views expressed here contain information derived from publicly available sources that have not Cyclopharm Limited been independently verified. Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia The presentation include certain statemen